Every 424B that Trinity Biotech Plc (TRIB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow TRIB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TRIB filings page.
Trinity Biotech plc updates a prospectus supplement registering the resale by selling shareholders of up to 33,752,429 ADSs, representing 675,048,580 Ordinary Shares. The offering is a secondary resale by holders and does not state proceeds to the company.
The supplement incorporates a Form 6-K announcing the launch of Trinovium, a new subsidiary targeting the AI data centre liquid cooling market, and discloses a June 22, 2026 ADS last reported sale price of $0.582.
Trinity Biotech plc files a prospectus supplement registering a secondary resale of up to 33,752,429 ADSs, representing 675,048,580 ordinary shares, for sale by selling shareholders from time to time. The resale is by the Selling Shareholders and not an issuer primary offering.
The supplement incorporates a Form 6-K disclosing Q1 2026 results and commercial updates: Q1 2026 revenue $10.8M (up 43% year-on-year), gross margin 35.4% (up from 25.2%), net loss $4.4M, and adjusted EBITDA -$1.1M. The company announced purchase orders for over 2 million TrinScreen HIV tests scheduled for fulfillment in Q3 2026. The ADS last reported sale price on June 17, 2026 was $0.5799.
Trinity Biotech plc filed a prospectus registering for resale up to 33,752,429 ADSs (each ADS = 20 ordinary shares) related to a Standby Equity Purchase Agreement with YA II PN, LTD., under which the company may sell up to $25 million of ADSs to the investor.
The prospectus states the resale is by the Selling Securityholder and that the company will not receive proceeds from resales; the company may, at its election, sell ADSs to the investor under the Purchase Agreement and could receive up to $25 million in aggregate gross proceeds if it elects to sell ADSs into the commitment.
Trinity Biotech plc is offering American Depositary Shares (ADSs) in an at-the-market program with Lucid Capital Markets, LLC for an aggregate offering price of up to $4,352,314. Each ADS represents 20 Ordinary Shares. The offering may be made from time to time under the ATM Sales Agreement and will be conducted as sales “at the market” under Rule 415(a)(4).
The prospectus supplement notes 405,017,380 Ordinary Shares outstanding as of June 10, 2026 and states a public float market value of approximately $13,056,942 based on an earlier closing price. Proceeds are intended for general corporate purposes, including working capital, and Lucid will receive a 3.0% commission on gross proceeds.
Trinity Biotech plc is registering the resale of up to 167,950,998 ADSs, representing up to 3,359,019,957 Ordinary Shares, for sale by Perceptive-affiliated selling shareholders pursuant to conversion rights and a convertible note. These ADSs may be issued on conversion of Conversion Obligations (together, the "Conversion Documents") and sold from time to time by the Selling Shareholders; the Company will receive no cash proceeds from such resales. Conversions are subject to a Beneficial Ownership Cap of 9.9% and a conversion floor price of $0.5061 per ADS; the ADS ratio is 1 ADS = 20 Ordinary Shares. The prospectus discloses resale methods, potential dilution if conversions occur, Nasdaq listing symbol TRIB, and that conversion reduces the outstanding indebtedness under the Credit Agreement.
Trinity Biotech plc is updating its Form F-1 prospectus to cover the resale by selling shareholders of up to 1,117,818,000 Ordinary Shares, represented by up to 55,890,900 ADSs. The ADSs trade on Nasdaq under the symbol TRIB and the last reported sale price on March 9, 2026 was $0.7010.
The supplement incorporates Form 6‑K materials filed March 10, 2026, including a press release describing technical breakthroughs for the company’s next‑generation CGM+ continuous glucose monitoring platform and a trading/business update that discloses a limited waiver and a covenant deferral under its Credit Agreement through July 1, 2026, and operational actions such as outsourcing Uni‑Gold™ HIV manufacturing.
Trinity Biotech plc updates its prospectus to register for resale up to 705,659,320 Ordinary Shares, represented by up to 35,282,966 ADSs. The supplement incorporates Form 6-K reports filed March 10, 2026, describing technical breakthroughs for its next‑generation CGM+ continuous glucose monitoring platform and a trading and business update.
The company reports substantial multi‑day clinical-data improvements in glucose measurement accuracy (material reduction in MARD), anticipates initiating a pivotal clinical trial in 2026, and states the CGM+ design targets modularity, multimodal sensing, and AI-native analytics. Separately, Trinity obtained a limited waiver and a covenant deferral under its credit agreement through July 1, 2026.
Trinity Biotech plc entered a standby equity purchase agreement allowing up to $25,000,000 of ADS purchases and registers up to 35,282,966 ADSs (each ADS = 20 ordinary shares). The Company delivered 175,537 Commitment ADSs as a fee and paid a $35,000 structuring fee. Under the Purchase Agreement the per-ADS purchase price equals 0.97 times the lowest daily VWAP in a three-Trading-Day period or 0.95 times the VWAP in a one-Trading-Day period. The Investor is subject to a 4.99% beneficial ownership cap; separate Perceptive conversion instruments include a 9.9% cap. The prospectus registers resale by YA II PN, LTD., and Trinity will not receive proceeds from resales; proceeds to Trinity, if any, would result only from ADSs Trinity elects to sell to the Investor under the Purchase Agreement. Shares outstanding figures and other capitalization metrics are reported in the prospectus.
Trinity Biotech plc files a prospectus supplement registering for resale up to 1,117,818,000 Ordinary Shares, represented by up to 55,890,900 ADSs, for sale by selling shareholders.
The supplement also furnishes Form 6-K disclosures: (1) a Nasdaq notice that the company does not meet the MVPHS $15,000,000 requirement and has until August 18, 2026 to regain compliance, and (2) a Standby Equity Purchase Agreement with YA II PN, Ltd. providing an up-to $25,000,000 financing commitment (term to February 24, 2029), an Aggregate Advance Share Cap of 35,107,429 ADSs, and a Commitment Fee of 175,537 ADSs.
Trinity Biotech plc filed a prospectus supplement covering the resale by selling shareholders of up to 1,117,818,000 Ordinary Shares, represented by up to 55,890,900 ADSs. The supplement incorporates a recent Form 6-K reporting that Nasdaq notified the company its ADSs no longer meet the minimum bid price requirement of US $1.00 per share after trading below that level for 30 consecutive business days. Trinity Biotech has 180 calendar days, until August 10, 2026, to regain compliance while its ADSs, which last traded at $0.77 on February 13, 2026, remain listed on the Nasdaq Global Select Market.
Trinity Biotech plc is registering up to 55,890,900 American Depositary Shares (ADSs), representing 1,117,818,000 Ordinary Shares, for resale by Perceptive-affiliated selling shareholders. These ADSs are issuable upon conversion of up to $60 million of a convertible note and related payment obligations under conversion agreements with Perceptive funds.
The ADS conversion price is 97% of the volume-weighted average price, subject to a $1.03 floor and a 9.9% beneficial ownership cap. The company will not receive cash from the resale of ADSs and will not receive cash from conversions, but each conversion reduces outstanding debt under the credit agreement and conversion rights. Ordinary Shares outstanding before the sale were 374,206,640, which means full conversion could significantly dilute existing holders, and the company already carries substantial indebtedness, including a term loan due in January 2027.